Apollon Wealth Management LLC Purchases 430 Shares of Sanofi $SNY

Apollon Wealth Management LLC lifted its position in Sanofi (NASDAQ:SNY) by 2.4% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 18,268 shares of the company’s stock after buying an additional 430 shares during the quarter. Apollon Wealth Management LLC’s holdings in Sanofi were worth $883,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in SNY. Nuveen LLC bought a new position in shares of Sanofi in the first quarter valued at $177,831,000. Federated Hermes Inc. grew its stake in shares of Sanofi by 58.5% in the first quarter. Federated Hermes Inc. now owns 3,947,583 shares of the company’s stock valued at $218,933,000 after buying an additional 1,456,269 shares in the last quarter. OLD Mission Capital LLC bought a new position in shares of Sanofi in the first quarter valued at $48,938,000. Raymond James Financial Inc. grew its stake in shares of Sanofi by 15.1% in the first quarter. Raymond James Financial Inc. now owns 3,244,027 shares of the company’s stock valued at $179,914,000 after buying an additional 425,597 shares in the last quarter. Finally, LPL Financial LLC grew its stake in shares of Sanofi by 18.4% in the first quarter. LPL Financial LLC now owns 1,520,721 shares of the company’s stock valued at $84,339,000 after buying an additional 236,625 shares in the last quarter. 14.04% of the stock is owned by institutional investors.

Analysts Set New Price Targets

SNY has been the subject of several analyst reports. Wall Street Zen raised shares of Sanofi from a “hold” rating to a “buy” rating in a research note on Saturday, August 2nd. Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a “hold” rating to a “buy” rating in a research report on Tuesday, September 2nd. Barclays reaffirmed an “overweight” rating on shares of Sanofi in a research report on Wednesday, July 2nd. JPMorgan Chase & Co. raised shares of Sanofi from a “neutral” rating to an “overweight” rating in a research report on Friday, August 8th. Finally, Morgan Stanley raised shares of Sanofi from an “equal weight” rating to an “overweight” rating and lifted their price objective for the stock from $56.00 to $58.00 in a research report on Monday, September 8th. Two investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $62.67.

Sanofi Stock Up 0.9%

SNY stock opened at $49.22 on Wednesday. The company has a market cap of $120.86 billion, a PE ratio of 11.83, a price-to-earnings-growth ratio of 1.19 and a beta of 0.51. The business has a 50-day simple moving average of $48.32 and a 200 day simple moving average of $49.70. Sanofi has a 52 week low of $44.62 and a 52 week high of $60.12. The company has a quick ratio of 0.94, a current ratio of 1.27 and a debt-to-equity ratio of 0.19.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings results on Thursday, July 31st. The company reported $0.90 EPS for the quarter, missing analysts’ consensus estimates of $0.96 by ($0.06). The company had revenue of $11.34 billion during the quarter, compared to analyst estimates of $9.91 billion. Sanofi had a net margin of 21.47% and a return on equity of 16.86%. The firm’s revenue for the quarter was down 7.0% compared to the same quarter last year. During the same period last year, the firm earned $1.73 EPS. Sell-side analysts anticipate that Sanofi will post 4.36 EPS for the current fiscal year.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.